Araceli Biosciences has added Oregon business executive Jeff Swickard as an investor in its recently completed $4.5 million financing round.
The funding supports Araceli’s cellular imaging platform, which helps pharmaceutical and biotechnology researchers test potential medicines using human cell-based assays.
These New Approach Methodologies are intended to provide information about drug safety and effectiveness while reducing reliance on animal testing.
Araceli’s Endeavor platform captures and analyzes how human cells respond to drug compounds. Its technology is designed to generate scalable and reproducible biological data earlier in the drug development process.
The company combines high-performance imaging with artificial intelligence analysis software. Its customers include 10 of the world’s 20 largest pharmaceutical companies, with a significant presence in the Bay Area, Boston, London, and Berlin.
Araceli expects its 2026 revenue to be approximately six times the level recorded during the comparable period two years earlier. The projection follows increasing adoption of AI-assisted research and human cell models across the pharmaceutical industry.
The Tigard, Oregon-based company is entering the second phase of its commercialization strategy. It plans to introduce consumable products optimized for its installed instrument base, with a broader launch expected in 2027.
Consumables could create a recurring revenue stream as customers conduct more experiments on Araceli systems. They may also help standardize workflows and improve consistency across laboratories.
Founded in 2020 and separated from Phoseon Technology in 2023, Araceli employs approximately 30 people, most of whom work in Oregon.
Swickard’s investment supports both the company’s commercial expansion and its role in Oregon’s technology and life sciences economy.
KEY QUOTES:
“By helping researchers test potential drugs on human cell models earlier in development, our technology delivers faster, more accurate answers while reducing reliance on animal testing.”
Shawn MacDonald, Chief Financial Officer of Araceli Biosciences
“We believe the future of science should be smarter, faster, and more humane. That future is already taking shape in Oregon, and we’re proud to be part of it.”
Jeff Swickard, Investor in Araceli Biosciences
